Author Archives: Marisa Wexler MS

European CHMP Gives Positive Opinion to COPD Therapy Trixeo Aerosphere

A committee from the European Medicines Agency (EMA) recommended that AstraZeneca‘s triple combination therapy Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) be approved as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The recommendation, from the EMA’s Committee for Medicinal Products for…

AstraZeneca’s New Data Shows Breztri Aerosphere Better for All Seasons

Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) outperformed Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe exacerbations in people with chronic obstructive pulmonary disease (COPD) during all seasons of the year, new data from the ETHOS clinical trial show. That data will be presented by…

FDA Approves Breztri Aerosphere as COPD Maintenance Treatment

AstraZeneca‘s Breztri Aerosphere has been approved by the U.S. Food and Drug Administration (FDA) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Formerly known as PT010, Breztri Aerosphere is an inhaled therapy with three active components: the long-acting muscarinic antagonist…

ProAir Digihaler for COPD and Asthma Now Available in US

The ProAir Digihaler, a digital inhaler designed for people with asthma and chronic obstructive pulmonary disease (COPD) to monitor their inhaler usage through the use of a mobile app, is now available by prescription in the U.S. The albuterol inhaler (albuterol sulfate, 117 micrograms), developed by Teva…

Lung Denervation System Named FDA Breakthrough Device

Nuvaira‘s Lung Denervation System, under clinical investigation for its use in treating chronic obstructive pulmonary disease (COPD), has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). This designation is given to devices that have the potential to substantially improve the…